Claudin-4 is aberrantly expressed in most epithelial ovarian carcinomas (17–19), and in up to 75% of HGSOC tumors, where it functions as a driver in the development of resistance to cancer therapeutics, ultimately leading to worse patient outcomes (2). This evidence concerns the gene CLDN4 and cancer.